EBV+ DLBCL upregulates at least three key cellular signaling pathways:AP-1, JAK/STAT, and NF-κB, ultimately leading to PD-L1 overexpression (11, 23). Here, NFKB1 is linked to diffuse large B-cell lymphoma.